{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:37:40Z","timestamp":1773931060533,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jiph.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:41:25Z","timestamp":1664282485000},"page":"1180-1191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach"],"prefix":"10.1016","volume":"15","author":[{"given":"Sivakumar","family":"Gangadharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenifer Mallavarpu","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Rajajagadeesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malathi","family":"Kullappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankargouda","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Harshini","family":"Gandhamaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishnu Priya","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna Kumari","family":"Nakkella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selvaraj","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Mohan","family":"Surapaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2022.09.007_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jiph.2022.09.007_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101619","article-title":"Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19","volume":"34","author":"Qu","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.jiph.2022.09.007_bib3","unstructured":"\u3008https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness.\u3009."},{"key":"10.1016\/j.jiph.2022.09.007_bib4","unstructured":"\u3008https:\/\/www.gov.uk\/government\/publications\/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19\u20138-december-2021\/nervtag-antiviral-drug-resistance-and-the-use-of-directly-acting-antiviral-drugs-daas-for-covid-19\u20138-december-2021\u3009."},{"key":"10.1016\/j.jiph.2022.09.007_bib5","doi-asserted-by":"crossref","first-page":"30679","DOI":"10.1073\/pnas.2007840117","article-title":"Analysis of genomic distributions of SARS-CoV-2 reveals a dominant strain type with strong allelic associations","volume":"117","author":"Yang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jiph.2022.09.007_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14760584.2020.1800463","article-title":"Vaccination against SARS-CoV-2 and disease enhancement\u2013knowns and unknowns","volume":"19","author":"Zellweger","year":"2020","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.jiph.2022.09.007_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-2600(21)00075-8","article-title":"SARS-CoV-2 evolution and vaccines: cause for concern?","volume":"9","author":"Williams","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiph.2022.09.007_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2022.09.007_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jiph.2022.09.007_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.molmed.2016.09.006","article-title":"Drug repurposing: new treatments for Zika virus infection?","volume":"22","author":"Cheng","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jiph.2022.09.007_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-8868-6_15","article-title":"In silico oncology drug repositioning and polypharmacology","author":"Cheng","year":"2019","journal-title":"Cancer Bioinforma"},{"key":"10.1016\/j.jiph.2022.09.007_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.jiph.2022.09.007_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jinf.2020.02.026","article-title":"COVID-19 spike-host cell receptor GRP78 binding site prediction","volume":"80","author":"Ibrahim","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2022.09.007_bib14","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jiph.2022.09.007_bib15","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.jiph.2022.09.007_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"issue":"78","key":"10.1016\/j.jiph.2022.09.007_bib17","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1128\/JVI.78.11.5619-5632.2004","article-title":"Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase","volume":"2004","author":"Ivanov","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jiph.2022.09.007_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2022.09.007_bib19","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.jiph.2022.09.007_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical\u2013therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart lung Transplant"},{"key":"10.1016\/j.jiph.2022.09.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jiph.2022.09.007_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2022.09.007_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.virusres.2017.01.023","article-title":"Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes","volume":"234","author":"Posthuma","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.jiph.2022.09.007_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The nonstructural proteins directing coronavirus RNA synthesis and processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.jiph.2022.09.007_bib25","first-page":"E3900","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jiph.2022.09.007_bib26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/postgradmedj-2020-137785","article-title":"Hydroxychloroquine and covid-19","volume":"96","author":"Sinha","year":"2020","journal-title":"Postgrad Med J"},{"issue":"11","key":"10.1016\/j.jiph.2022.09.007_bib27","first-page":"1","article-title":"A computational study of cooperative binding to multiple SARS-CoV-2 proteins","volume":"2021","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2022.09.007_bib28","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","article-title":"Use of antiviral drugs to reduce COVID-19 transmission","volume":"8","author":"Mitj\u00e0","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jiph.2022.09.007_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3906\/sag-2004-145","article-title":"Antiviral treatment of COVID-19","volume":"50","author":"Yavuz","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jiph.2022.09.007_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2187","article-title":"Efficacy and safety of remdesivir in hospitalized Covid\u201019 patients: systematic review and meta\u2010analysis including network meta\u2010analysis","volume":"31","author":"Elsawah","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jiph.2022.09.007_bib31","unstructured":"\u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04575597\u3009."},{"key":"10.1016\/j.jiph.2022.09.007_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jiph.2022.09.007_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jmv.25761","article-title":"The potential chemical structure of anti\u2010SARS\u2010CoV\u20102 RNA\u2010dependent RNA polymerase","volume":"92","author":"Lung","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2022.09.007_bib34","doi-asserted-by":"crossref","unstructured":"L Zhang, R Zhou, Binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase; 2020.","DOI":"10.20944\/preprints202003.0267.v1"},{"issue":"11","key":"10.1016\/j.jiph.2022.09.007_bib35","first-page":"1","article-title":"Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models","volume":"6","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2022.09.007_bib36","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.ijbiomac.2020.09.098","article-title":"Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach","volume":"163","author":"Parvez","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jiph.2022.09.007_bib37","first-page":"1","article-title":"Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19","volume":"17","author":"Rafi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jiph.2022.09.007_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2021.100041","article-title":"A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme","volume":"98","author":"Ercan","year":"2021","journal-title":"J Indian Chem Soc"},{"key":"10.1016\/j.jiph.2022.09.007_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06435","article-title":"Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: a computational hierarchical investigation","volume":"7","author":"Hasan","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.jiph.2022.09.007_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2022.09.007_bib41","article-title":"In silico molecular docking and molecular dynamic simulation analysis of phytochemicals from indian foods as potential inhibitors of SARS-CoV-2 RdRp and 3CLpro","volume":"16","author":"Qazi","year":"2020","journal-title":"Nat Prod Commun"},{"key":"10.1016\/j.jiph.2022.09.007_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1515\/chem-2021-0024","article-title":"Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19","volume":"19","author":"Abdellatiif","year":"2021","journal-title":"Open Chem"},{"key":"10.1016\/j.jiph.2022.09.007_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2022.09.007_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1478-3231.2008.01896.x","article-title":"Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms","volume":"28","author":"Hofmann","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jiph.2022.09.007_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejmech.2015.08.016","article-title":"Synthesis and inhibitory effects of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus H1N1","volume":"102","author":"Lin","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jiph.2022.09.007_bib46","first-page":"5","article-title":"Current landscape of antiviral drug discovery","author":"Blair","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.jiph.2022.09.007_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/fvl-2020-0050","article-title":"Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections","volume":"15","author":"Fani","year":"2020","journal-title":"Future Virol"},{"key":"10.1016\/j.jiph.2022.09.007_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01517-z","article-title":"In vitro and in vivo studies reveal \u03b1-Mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus","volume":"18","author":"Patil","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.jiph.2022.09.007_bib49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41401-019-0316-7","article-title":"[1, 2, 4] Triazolo [1, 5-a] pyrimidine derivative (Mol-5) is a new NS5-RdRp inhibitor of DENV2 proliferation and DENV2-induced inflammation","volume":"41","author":"Wan","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jiph.2022.09.007_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01663-1","article-title":"Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus","volume":"18","author":"Yuan","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.jiph.2022.09.007_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2015\/934594","article-title":"Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection","volume":"26","author":"Zhanel","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jiph.2022.09.007_bib52","doi-asserted-by":"crossref","unstructured":"C Lee, TJ Louie, K Weiss, L Valiquette, M Gerson, W Arnott, SL Gorbach, Fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes. Canad J Infect Diseases Med Microbiol; 2016.","DOI":"10.1155\/2016\/8048757"},{"key":"10.1016\/j.jiph.2022.09.007_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2022.09.007_bib54","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1128\/AAC.06282-11","article-title":"Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects","volume":"56","author":"Vourvahis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.09.007_bib55","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.jiph.2022.09.007_bib56","first-page":"3","article-title":"Exploring the polymerase activity of chikungunya viral non structural protein 4 (nsP4) using molecular modeling, epharmacophore and docking studies","author":"Kumar","year":"2012","journal-title":"Int J Pharm Life Sci"},{"key":"10.1016\/j.jiph.2022.09.007_bib57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fmolb.2021.671263","article-title":"Current strategies of antiviral drug discovery for COVID-19","volume":"8","author":"Mei","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jiph.2022.09.007_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251801","article-title":"Natural plant products as potential inhibitors of RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus-2","volume":"16","author":"Koulgi","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2022.09.007_bib59","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2022.09.007_bib60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cryst11050471","article-title":"Virtual screening and molecular docking studies for discovery of potential RNA-dependent RNA polymerase inhibitors","volume":"11","author":"Ghazwani","year":"2021","journal-title":"Crystals"},{"key":"10.1016\/j.jiph.2022.09.007_bib61","first-page":"8","article-title":"Molecular dynamics simulations reveal the interaction fingerprint of remdesivir triphosphate pivotal in allosteric regulation of SARS-CoV-2 RdRp","author":"Srivastava","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jiph.2022.09.007_bib62","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1039\/D1RA07447D","article-title":"Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase","volume":"12","author":"Elfiky","year":"2022","journal-title":"RSC Adv"},{"key":"10.1016\/j.jiph.2022.09.007_bib63","first-page":"11","article-title":"Identification of natural inhibitors against SARS-CoV-2 drugable targets using molecular docking, molecular dynamics simulation, and MM-PBSA approach","author":"Kushwaha","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"583","key":"10.1016\/j.jiph.2022.09.007_bib64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-Cov-2 protein interaction map reveals targets for drug repurposing","volume":"2020","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2022.09.007_bib65","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1166\/jnn.2020.18955","article-title":"Interactions between remdesivir, ribavirin, favipiravir, Galidesivir, hydroxychloroquine and chloroquine with fragment molecular of the COVID-19 main protease with inhibitor N3 complex (PDB ID: 6LU7) using molecular docking","volume":"20","author":"Silva Arouche","year":"2020","journal-title":"J Nanosci Nanotechnol"},{"key":"10.1016\/j.jiph.2022.09.007_bib66","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jiph.2022.09.007_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04502","article-title":"SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)\u2013A drug repurposing study","volume":"6","author":"Ahmad","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jiph.2022.09.007_bib68","first-page":"1","article-title":"Elucidating the role of N440K mutation in SARS-CoV-2 spike\u2013ACE-2 binding affinity and COVID-19 severity by virtual screening, molecular docking and dynamics approach","volume":"8","author":"Kullappan","year":"2021","journal-title":"J Biomol Struct Dyn"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:15:20Z","timestamp":1761750920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1876034122002441"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.09.007","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}